Register
Login:
Share:
Email Facebook Twitter

Add Immupharma to quick picks

Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 57.00Bid: 56.00Ask: 58.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 2.00Spread as %: 3.57%Open: 54.75High: 57.00Low: 54.75Yesterday’s Close: 57.00

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
57.00

Share Price SpacerBid
56.00

Share Price SpacerAsk
58.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
162,124

Share Price SpacerOpen
54.75

Share Price SpacerHigh
57.00

Share Price SpacerLow
54.75

Share Price SpacerClose
57.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 88.62m £50.51m 5,000

52 Week High 66.00 52 Week High Date 3-NOV-2014
52 Week Low 41.50 52 Week Low Date 9-JUN-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
18 0 162,124 -12.611 -4.52 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

21-Nov-14
16:28:41
57.50
953
Buy* 
56.00
58.00
547.98
Trade Type:
Ordinary

21-Nov-14
14:17:50
57.50
1,100
Buy* 
56.00
57.50
632.50
Trade Type:
Ordinary

21-Nov-14
13:58:05
57.00
1,250
Buy* 
56.00
57.00
712.50
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
23-Jan-12Buy
Trade Notifier Information for Immupharma
Franco Di Muzio held the position of Non-Executive Director at Immupharma at the time of this trade.
 Franco Di Muzio
81GBX60,9500
View more Immupharma directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Sat 10:20
Goyathlay
Comparison of results
57.00
No Opinion

Ok, Comparing the Lupuzor (LUP) and Epratuzumab (EPR) articles Both were Phase IIb randomised, double-blind and placebo-controlled. INCLUSION CRITERIA: In the EPR study there was a composite index of symptoms BICLA whereas the LUP group relied on just the SLEDAI-2K index. Existing therapy differed for example, in the EPR study any patients taking Prednisolone must have had a maximum of 5-60mg per day whereas in the LUP study patients must not have received a WEEKLY equivalent of 80mg of Prednisolone. There were other differences in existing therapy requirements. ADVERSE EVENTS: In both studies AEs didn't appear to be any different to placebo (p3 Lupuzor and p6 Epratuzumab) EFFICACY: The EPR trial was not 'chosen based on statistical powering requirements'. Indeed, 'the overall test of treatment effect was not statistically significant' (p = 0.148) However, 'Exploratory pairwise analysis using the BICLA endpoint found a higher proportion of responders in all arms than with placebo (23.7–45.9%, vs 21.1% placebo)' The LUP trial showed response rates for LUP every 4/52 compared to placebo as 67.6% v 41.5% at week 12 and 84.2 v 45.8% at week 24. "The results show a clinical and statistical improvement in disease activity." These are just selected quotes from the two papers. I am no statistician and may just be a ramping, pom-pom wielding cheerleader . Cheerleaders you say. Oh go on then, if you insist: http://tinyurl.com/bqh9re6
Fri 22:26
Goyathlay
RE: The Missing Link
57.00
No Opinion

My Uncle, who was a Consultant Haematologist on Long Island, used to charge $3000/hour about 15 years ago. It looks like pro bono work compared to $2000 for a couple of stitches. I wonder how much is dictated by the cost of professional indemnity insurance etc. ( Lupuzor @ $15,000 per year is looking like a giveaway price now.) NHS Medical Staff? No more than one in 1000 I would guess ;)
Fri 22:08
boomorbust
RE: The Missing Link
57.00
No Opinion

..........from my last post http://www.nytimes.com/2013/12/03/health/as-hospital-costs-soar-single-stitch-tops-500.html?adxnnl=1&pagewanted=all&adxnnlx=1416607267-jHMdDLaGv57JNyEsDidesA Re. the 1.7m NHS staff - wonder how many of those are actually medical staff.
Fri 21:57
Goyathlay
The Missing Link
57.00
No Opinion

http://tinyurl.com/8y2zyos
Fri 21:56
Goyathlay
Boom
57.00
No Opinion

I am afraid we are BOTH missing the most significant cost element which is course the Hospital Parking Charges ;) You are right, I do like a bit of Healthcare trivia. I always thought that the NHS was the second biggest employer in the World behind the Indian Railways. No, apparently it is in Fifth just behind McDeath, that purveyor of nutritionally balanced meals which are both rainforest and blood-lipid neutral .
Fri 21:42
boomorbust
Goy
57.00
No Opinion

Yes you are probably right but in the US it makes a huge difference to the cost of treatment if it can be carried out at a doctor's surgery as opposed to in hospital - see article in link. As you say though it we'll just have to wait for those phase III results. In the meantime as we are discussing medical costs in the US - a mildly interesting fact for you:- "If the health-care system were to break off from the United States and become its own economy, it would be the fifth-largest in the world. "It would be bigger than the United Kingdom or France and only behind the United States, China, Japan and Germany," says David Blumenthal, executive director of the non-profit Commonwealth Fund.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.